🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesMy blood pressure normalization journey — off 2 antihypertensives Page 6

My blood pressure normalization journey — off 2 antihypertensives

BethLabQueen Sat, May 16, 2026 at 5:28 PM 27 replies 640 viewsPage 6 of 6
Dr.EndoEP
Member
267
1,234
Oct 2024
El Paso, TX
May 25, 2026 at 7:50 PM#26

Adding the clinical framing, because it changes how the question reads.

TirzTom said:
...we don't know the long-term effects of cardiovascular risk...

This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.

However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.

Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.

16 16NicoleRaleigh, james_edin, FranDenver and 13 others
Reply Quote Save Share Report
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
May 26, 2026 at 5:06 AM#27
Dr.EndoEP said:
TirzTom said: ...we don't know the long-term effects of cardiovascular risk...

Same pattern here, and in the same order. Posting only so the count is not one.

15 15roxy_nash, tony_orlando, Dr.NephBHM_UK and 12 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
May 26, 2026 at 2:22 PM#28
Dr.EndoEP said:
TirzTom said: ...we don't know the long-term effects of cardiovascular risk...

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 52" → 34" ✅ Resolved
  2. Triglycerides: 224 → 114 ✅ Resolved
  3. HDL: 36 → 56 ✅ Resolved
  4. Blood pressure: 144/94 → 122/76 ✅ Resolved
  5. Fasting glucose: 119 → 88 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

14 14HealthEcon_DC, PedsEndoPhilly, SleepDoc_PDX and 11 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
May 26, 2026 at 11:38 PM#29
Dr.EndoEP said:
TirzTom said: ...we don't know the long-term effects of cardiovascular risk...
Dr.EndoEP said:
...we're creating a generation dependent on cardiovascular risk...

I understand the concern, but consider this analogy: are we "creating a generation dependent on" blood pressure medication? Cholesterol medication? Thyroid medication?

Obesity is a chronic disease with biological drivers. Treating it with medication is no different from treating any other chronic condition. The "dependency" framing implies weakness or moral failure — neither of which is accurate.

If ongoing medication is what keeps someone healthy, that's successful treatment, not dependency.

13 13Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 10 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
May 27, 2026 at 8:53 AM#30
Dr.MetabolicMD said:
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 13 months of treatment.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -2.4 lbs/week average
Fasting glucose (finger stick): stable at 83 mg/dL
Blood pressure (home): 119/73 average
Resting heart rate: 63 bpm (down from 79)
Waist circumference: down 13 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

41 16wei_SG, cory_ATX, lori_vegas and 38 others
Reply Quote Save Share Report
1456

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register